This session will cover key concepts related to implementing intensity modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT) gastrointestinal (GI) cancers. Updates on clinical outcome data using IMRT and SBRT, including survival and toxicity, will be presented. In addition, practical concepts on simulation, treatment planning, patient setup and quality assurance will be discussed. Disease sites that will be covered are anorectal cancers, pancreatic cancers and esophago-gastric cancers. Finally, a case panel will present cases highlighting how these concepts are used in real-life situations.
This program is designed to meet the interest of radiation oncologists, physicists, radiation dosimetrists, radiation therapists.
- Explain normal tissue toxicity for relevant normal organs along the GI tract.
- Discuss strategies for image guidance, motion management and treatment planning for IMRT and SBRT for GI cancers.
- Daniel T. Chang, MD, is employed at Stanford University and has no financial relationships with a commercial interest.
- Laura A. Dawson, MD, is employed Princess Margaret Hospital and receives research grants from Bayer and Raysearch.
- Mary U. Feng, MD, is employed at the University of Michigan and receives compensation from Varian, NIH, Blue Cross Blue Shield and RSNA and holds a leadership position with NCCN.
- Sasa Mutic, PhD, is employed at Washington University, San Diego and receives compensation from Varian and ViewRay and holds a leadership position with Radialogica, LLC.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.